FDA hands down approval for Bristol Myers' lung cancer drug from Turning Point buyout
Bristol Myers Squibb’s $4.1 billion buyout of Turning Point Therapeutics has paid off, with the FDA handing down an approval of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
